文献速递生殖医学

用于体外受精/卵胞浆内单精子注射中优化卵巢刺激的促性腺激素剂量选择模型的开发与验证:个体参与者数据荟萃分析

Development and validation of a gonadotropin dose selection model for optimized ovarian stimulation in IVF/ICSI: an individual participant data meta-analysis.
PubMed 文献 · Hum Reprod Update · 2025-01-01

该个体参与者数据荟萃分析纳入14项随机对照试验共3455名参与者,最终纳入2907名39岁以下女性,开发并验证促性腺激素起始剂量选择模型。活产预测模型区分度低(AUC 0.557),而治疗风险预测模型区分度良好(AUC 0.769)。模型显示调整起始剂量对活产预测能力差,但对卵巢过度刺激综合征等风险预测充分。

要点

  • 共纳入14项RCT、3455名参与者,排除39岁及以上后最终分析2907名女性。
  • 活产预测模型包含年龄、起始剂量、BMI、AFC、IVF/ICSI和AMH,AUC为0.557。
  • 治疗风险预测模型包含年龄、起始剂量、AMH和bFSH(或GnRH类似物),AUC为0.769。

核心结论

  • 该剂量选择模型对通过调整FSH起始剂量预测活产能力差,但对预测OHSS发生和治疗风险充分。
  • 模型由易于获取的患者特征组成,有助于为每位患者选择最佳促性腺激素起始剂量以降低治疗风险并可能减少治疗费用。

研究设计与样本

  • 个体参与者数据荟萃分析,检索MEDLINE、EMBASE和CRSO数据库,最后检索日期为2022年7月13日。
  • 纳入比较不同促性腺激素剂量的RCT,需报告至少一种卵巢储备试验并报告活产或持续妊娠。
  • 共纳入14项RCT、3455名参与者,排除39岁及以上女性后最终纳入2907名女性。
  • 采用广义线性混合多水平模型进行预测变量选择和模型开发。

主要发现

  • 活产最优预测模型包含年龄、促性腺激素起始剂量、BMI、AFC、IVF/ICSI和AMH,AUC为0.557(95%CI 0.536-0.577)。
  • 临床可行的活产模型包含年龄、起始剂量和AMH,AUC为0.554(95%CI 0.530-0.578)。
  • 两个治疗风险最优模型性能相同,AUC均为0.769(95%CI 0.729-0.809);一个包含年龄、起始剂量、AMH和bFSH,另一个还包含GnRH类似物。
  • 临床可行的治疗风险模型包含年龄、起始剂量、AMH和GnRH类似物,AUC为0.748(95%CI 0.709-0.787)。

关键数值与推荐

  • 活产最优模型预测变量:年龄、促性腺激素起始剂量、BMI、AFC、IVF/ICSI、AMH,AUC 0.557(95%CI 0.536-0.577)。
  • 临床可行活产模型预测变量:年龄、起始剂量、AMH,AUC 0.554(95%CI 0.530-0.578)。
  • 治疗风险最优模型(两个)AUC均为0.769(95%CI 0.729-0.809)。
  • 临床可行治疗风险模型预测变量:年龄、起始剂量、AMH、GnRH类似物,AUC 0.748(95%CI 0.709-0.787)。

临床怎么用

  • 该剂量选择模型基于易于获取的患者特征,可辅助选择最佳促性腺激素起始剂量以降低治疗风险并可能减少治疗费用。
  • 模型对通过调整FSH起始剂量预测活产能力差,但对预测OHSS发生和治疗风险充分。

局限性

  • 活产预测模型区分度低,最优模型AUC为0.557(95%CI 0.536-0.577),临床可行模型AUC为0.554(95%CI 0.530-0.578)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The ovarian response to gonadotropin stimulation varies widely among women, and could impact the probability of live birth as well as treatment risks. Many studies have evaluated the impact of different gonadotropin starting doses, mainly based on predictive variables like ovarian reserve tests (ORT) including anti-Müllerian hormone (AMH), antral follicle count (AFC), and basal follicle-stimulating hormone (bFSH). A Cochrane systematic review revealed that individualizing the gonadotropin starting dose does not affect efficacy in terms of ongoing pregnancy/live birth rates, but may reduce treatment risks such as the development of ovarian hyperstimulation syndrome (OHSS). An individual patient data meta-analysis (IPD-MA) offers a unique opportunity to develop and validate a universal prediction model to help choose the optimal gonadotropin starting dose to minimize treatment risks without affecting efficacy. OBJECTIVE AND RATIONALE: The objective of this IPD-MA is to develop and validate a gonadotropin dose-selection model to guide the choice of a gonadotropin starting dose in IVF/ICSI, with the purpose of minimizing treatment risks without compromising live birth rates. SEARCH METHODS: Electronic databases including MEDLINE, EMBASE, and CRSO were searched to identify eligible studies. The last search was performed on 13 July 2022. Randomized controlled trials (RCTs) were included if they compared different doses of gonadotropins in women undergoing IVF/ICSI, presented at least one type of ORT, and reported on live birth or ongoing pregnancy. Authors of eligible studies were contacted to share their individual participant data (IPD). IPD and information within publications were used to determine the risk of bias. Generalized linear mixed multilevel models were applied for predictor selection and model development. OUTCOMES: A total of 14 RCTs with data of 3455 participants were included. After extensive modeling, women aged 39 years and over were excluded, which resulted in the definitive inclusion of 2907 women. The optimal prediction model for live birth included six predictors: age, gonadotropin starting dose, body mass index, AFC, IVF/ICSI, and AMH. This model had an area under the curve (AUC) of 0.557 (95% confidence interval (CI) from 0.536 to 0.577). The clinically feasible live birth model included age, starting dose, and AMH and had an AUC of 0.554 (95% CI from 0.530 to 0.578). Two models were selected as the optimal model for combined treatment risk, as their performance was equal. One included age, starting dose, AMH, and bFSH; the other also included gonadotropin-releasing hormone (GnRH) analog. The AUCs for both models were 0.769 (95% CI from 0.729 to 0.809). The clinically feasible model for combined treatment risk included age, starting dose, AMH, and GnRH analog, and had an AUC of 0.748 (95% CI from 0.709 to 0.787). WIDER IMPLICATIONS: The aim of this study was to create a model including patient characteristics whereby gonadotropin starting dose was predictive of both live birth and treatment risks. The model performed poorly on predicting live birth by modifying the FSH starting dose. On the contrary, predicting treatment risks in terms of OHSS occurrence and management by modifying the gonadotropin starting dose was adequate. This dose-selection model, consisting of easily obtainable patient characteristics, aids in the choice of the optimal gonadotropin starting dose for each individual patient to lower treatment risks and potentially reduce treatment costs.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Schouten N, Wang R, Torrance H, et al. Development and validation of a gonadotropin dose selection model for optimized ovarian stimulation in IVF/ICSI: an individual participant data meta-analysis. Hum Reprod Update. 2025. PMID: 39707165. doi:10.1093/humupd/dmae032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。